Viome lands $86.5m and US retail deal for gut health test

Consumer longevity company’s Gut Intelligence Test to be sold in 200 CVS locations.

Preventative health and longevity company, Viome Life Sciences has secured $86.5 million in an oversubscribed Series C funding round. Major investors in the round include Khosla Ventures, Bold Capital and WRG Ventures, bringing the total raised by the company to $175 million. Viome says the funding will be used to support further R&D and retail expansion.

Founded in 2016, Viome is on a mission to improve health by addressing the root causes of chronic diseases, cancer, and aging. By harnessing insights into the microbiome’s interactions with individuals, the company aims to empower people with actionable recommendations for a long and healthy life.

Viome’s approach provides tailored recommendations based on individual human and microbial gene expressions. Using AI and machine learning, Viome has harnessed data from over 600,000 samples to create personalized at-home tests and health products. These include custom supplement formulas and tailored biotic blends to support gut and oral microbiome health.

“We made the strategic decision to invest in Viome, recognizing the groundbreaking fusion of its one-of-a-kind RNA technology with state-of-the-art AI,” said Robbie Schwietzer, Partner at Khosla Ventures. “Coupled with an unparalleled repository of biological data, this synergy doesn’t just hint at a revolution; it marks the dawn of a new era in healthcare.”

CVS deal for gut health test

Along with its new funding, Viome also announced that its Gut Intelligence Test is to be sold in 200 locations of CVS, the leading retail pharmacy in the United States. Available both in-store and online, the company says its gut test will be the “first-ever” to be sold by the retail chain, highlighting growing consumer demand for health optimization tools.

Viome lands $86.5m and national retail deal for gut health test

“In a world where healthcare has often been reactive, treating symptoms and targeting diseases only after they manifest, Viome is pioneering a transformative shift by harnessing the innate power of food and nutrition,” said Naveen Jain, CEO of Viome. “Our mission is not just to prolong life but to enrich it, enabling everyone to thrive in health and vitality. At Viome, we’re empowering our customers with an individualized nutrition strategy, cutting through the noise of temporary trends and one-size-fits-all advice.”

“The promise here is staggering: the very prevention of an epidemic wave of chronic diseases, spanning mental, metabolic, cognitive, and digestive health,” added Schwietzer. “Our partnership with Viome isn’t just an investment; it’s a commitment to medical innovation. We’re not merely excited; we’re inspired and resolved to continue supporting Viome as they sculpt the future with revolutionary products that will redefine the paradigms of health, from early-stage cancer diagnostics to personalized nutrition solutions that respond to the individual’s unique biological signature.”

Photos: Viome Life Sciences